Favipiravir
- Generic Name
- Favipiravir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4FN3O2
- CAS Number
- 259793-96-9
- Unique Ingredient Identifier
- EW5GL2X7E0
- Background
Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
...
- Indication
⑴用于埃博拉病毒感染的治疗。
⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）
- Associated Conditions
- Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza
- Associated Therapies
- -
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
- Conditions
- Interventions
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Ina-Respond
- Target Recruit Count
- 130
- Registration Number
- NCT04613271
- Locations
- 🇮🇩
RSPI Sulianti Saroso, Jakarta, DKI Jakarta, Indonesia
🇮🇩RSJ Soerodjo, Magelang, Central Java, Indonesia
🇮🇩RSUP Dr. Kariadi, Semarang, Central Of Java, Indonesia
The Prevent Severe COVID-19 (PRESECO) Study
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Appili Therapeutics Inc.
- Target Recruit Count
- 1187
- Registration Number
- NCT04600895
- Locations
- 🇺🇸
Quality Professional HealthCare, Miami, Florida, United States
🇺🇸Continental Clinical Research, LLC, Miami, Florida, United States
🇺🇸Sanitas Research, LLC, Miami, Florida, United States
Clinical Trial of Favipiravir Treatment of Patients With COVID-19
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- University of Pecs
- Target Recruit Count
- 14
- Registration Number
- NCT04600999
- Locations
- 🇭🇺
First Department of Internal Medicine, University of Szeged, Szeged, Hungary
🇭🇺National Korányi Institute for Pulmonology, Budapest, Hungary
🇭🇺Institute of Infectology, University of Debrecen, Debrecen, Hungary
The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 100
- Registration Number
- NCT04558463
- Locations
- 🇮🇩
Cipto Mangunkusumo National Referral Hospital, Jakarta, DKI Jakarta, Indonesia
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Promomed, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT04542694
- Locations
- 🇷🇺
City Hospital N40 of Kurortny District, Saint Petersburg, Russian Federation
🇷🇺Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation
🇷🇺Smolensk clinical hospital №1, Smolensk, Russian Federation
Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 353
- Registration Number
- NCT04529499
- Locations
- 🇰🇼
Jaber Al-Ahmad Al-Sabah Hospital (South Surra), Kuwait City, Kuwait
🇰🇼Mishref Field Hospital (Mishref), Kuwait City, Kuwait
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 168
- Registration Number
- NCT04501783
- Locations
- 🇷🇺
Medical center LLC "Neuroprofi", Korolev, Russian Federation
🇷🇺State budgetary institution of health care of the city of Moscow "City Clinical Hospital №52 of the Moscow City Healthcare Department", Moscow, Russian Federation
🇷🇺State budgetary institution of health care of the city of Moscow "City Clinical Hospital №67 n.a. LA Vorokhobova of the Moscow City Healthcare Department", Moscow, Russian Federation
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
- Conditions
- Interventions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- University College, London
- Target Recruit Count
- 240
- Registration Number
- NCT04499677
- Locations
- 🇬🇧
Royal Free Hospital, London, United Kingdom
🇬🇧University College London Hospital (UCLH), London, United Kingdom
Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Genuine Research Center, Egypt
- Target Recruit Count
- 26
- Registration Number
- NCT04478448
- Locations
- 🇪🇬
Genuine Research Center GRC, Cairo, Egypt
Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Ministry of Health, Turkey
- Target Recruit Count
- 1000
- Registration Number
- NCT04474457
- Locations
- 🇹🇷
Hacettepe University, School of Medicine, Ankara, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.